icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

Opioid crisis settled? US judge grants Sackler family IMMUNITY in $4.5bn bankruptcy deal for OxyContin maker Purdue Pharma

Opioid crisis settled? US judge grants Sackler family IMMUNITY in $4.5bn bankruptcy deal for OxyContin maker Purdue Pharma
Purdue Pharma, the maker of the powerful opioid OxyContin, will be dissolved after a federal judge approved a $4.5 billion settlement deal with the firm’s owners, who will be granted immunity from future lawsuits in exchange.

Judge Robert Drain of the US Bankruptcy Court in White Plains, New York authorized the settlement on Wednesday, forcing the Sackler family – which owns Purdue – to shell out more than $4 billion and dissolve the company after a flurry of lawsuits linked to OxyContin and its role in America’s opioid crisis.

“This is a bitter result,” Drain said of the deal, which released the Sacklers from future liability in opioid-related civil cases. The judge noted that Purdue’s products had contributed to a “massive public health crisis” that’s led to hundreds of thousands of overdose deaths and a wave of addiction, and voiced frustration that large amounts of the Sacklers’ family fortune is stored in offshore accounts.

I believe that at least some of the Sackler parties have liability for those [OxyContin] claims... I wish the plan had provided for more, but I will not jeopardize what the plan does provide.

Also on rt.com McKinsey told OxyContin producer to pay off distributors for every attributable overdose, court papers show – report

The agreement comes after two years of closed-door negotiations, launched after Purdue filed for bankruptcy, restructuring in 2019 as it faced some 2,900 lawsuits, more than 600 of which named members of the Sackler family, according to the New York Times.

Wednesday’s settlement will end those suits, which had been brought by governments, hospitals and individuals alleging harm caused by Purdue’s opioid products. The $4.5 billion will be paid in installments over a period of nine years, and will largely go to fund addiction treatment centers around the country.

While the deal does not forbid criminal prosecution for the family, to date no government or individual has attempted to press criminal charges against the Sacklers, as such cases are more difficult to prove in court. Purdue itself, however, pleaded guilty to criminal charges last year in a fraud case linked to its opioid sales.

The US Department of Justice, along with attorneys general for nine states and Washington, DC, vocally opposed the settlement plan, with the DOJ filing a series of briefs in recent weeks urging Drain to reject the deal. “Due process requires that those with litigation claims have reasonable opportunity to be heard,” DOJ lawyer Paul Schwartzberg argued during the trial.

Opponents also insisted the $4.5 billion settlement amounted to a slap on the wrist for the wealthy Sacklers, who reportedly raked in some $10 billion from Purdue between 2008 and 2017. A Congressional committee probing the family earlier this year, moreover, estimated it had a combined worth of around $11 billion.

Several states have already signaled plans to appeal the decision, including the attorney general for Washington state, Bob Ferguson, who blasted the settlement as “morally and legally bankrupt,” arguing that it “allows the Sacklers to walk away as billionaires with a lifetime legal shield.”

Also on rt.com Sackler family behind OxyContin busted trying to hide $1bn as lawsuits over opioid crisis pile up

Think your friends would be interested? Share this story!

Podcasts